Group 1 - The core point of the news is that BeiGene's stock price has dropped by 5.27%, currently trading at 264.50 CNY per share, with a total market capitalization of 407.51 billion CNY [1] - BeiGene was established on October 28, 2010, and went public on December 15, 2021. The company focuses on the research, development, production, and commercialization of innovative drugs, with 99.10% of its revenue coming from drug sales and 0.90% from collaboration arrangements [1] Group 2 - Morgan Stanley's fund holds a significant position in BeiGene, with the Morgan Stanley Health Industry Mixed A Fund (002708) maintaining 231,800 shares, unchanged from the previous period, representing 4.12% of the fund's net value [2] - The Morgan Stanley Health Industry Mixed A Fund has a total size of 1.423 billion CNY and has experienced a loss of 0.47% this year, ranking 8462 out of 8887 in its category, while its one-year return is 0.89%, ranking 7892 out of 8134 [2] Group 3 - The fund manager of the Morgan Stanley Health Industry Mixed A Fund is Wang Dapeng, who has been in the position for 11 years and 39 days, with the fund's total asset size at 1.997 billion CNY. The best return during his tenure is 70.7%, while the worst return is -50.91% [3]

Group 1 - The core point of the news is that BeiGene's stock price has dropped by 5.27%, currently trading at 264.50 CNY per share, with a total market capitalization of 407.51 billion CNY [1] - BeiGene, established on October 28, 2010, is located in Beijing and specializes in the research, development, production, and commercialization of innovative drugs, with 99.10% of its revenue coming from drug sales and 0.90% from collaboration arrangements [1] Group 2 - From the perspective of major fund holdings, CITIC Prudential Fund has a significant position in BeiGene, holding 11,900 shares in its CITIC Prudential CSI 800 Pharmaceutical Index Fund (LOF) A, which accounts for 1.99% of the fund's net value, ranking it as the tenth largest holding [2] - The CITIC Prudential CSI 800 Pharmaceutical Index Fund (LOF) A was established on January 1, 2021, with a current size of 147 million CNY, and has reported a year-to-date return of 1.77% and a one-year return of 16.18% [2] - The fund manager, Huang Zhi, has been in the position for 7 years and 219 days, overseeing assets totaling 4.418 billion CNY, with the best fund return during his tenure being 146.63% and the worst being -26.08% [2]

Group 1 - The Livermore Chinese concept stock index experienced a slight decline of 0.1% at the beginning of trading on February 25 [1] - Among the constituent stocks, BeiGene saw a drop of over 3% [1] - Tencent Music, Xpeng Motors, and NetEase each fell by more than 2% [1]

Group 1 - The Hang Seng Technology Index ETF (513180.SH) and the Hang Seng Internet ETF (513330.SH) have started the year on a downward trend, with major stocks like Alibaba, Tencent, and Xiaomi facing adjustments [1] - Following the Chinese New Year holiday, the market has shown weak performance due to revised expectations for interest rate cuts by the Federal Reserve, which is particularly impactful for the Hong Kong stock market sensitive to external liquidity [1] - The Federal Reserve's January meeting minutes revealed significant divergence among officials regarding future policy outlook, leading to a market perception that the pace of interest rate cuts may slow down in the short term [1] Group 2 - The initial jobless claims in the U.S. indicate that the employment market remains resilient, which is a key focus for the Federal Reserve during the interest rate cut cycle, resulting in reduced expectations for rate cuts [1] - The December PCE data released on February 20 exceeded expectations, reinforcing the view that the Federal Reserve may pause interest rate cuts, with market expectations for a June rate cut dropping to 45.6% and postponing the cut to July [1] - The Zhang Xia team from China Merchants Securities commented that while short-term expectations for Federal Reserve policy may fluctuate, the most significant phase of liquidity shock has passed, and once rate cut expectations stabilize, the Hong Kong market will benefit significantly [1] Group 3 - Investment tools focusing on Hong Kong technology-related ETFs include the Hang Seng Technology Index ETF (513180.SH), the Hang Seng Internet ETF (513330.SH), and the Hong Kong Stock Connect Technology ETF (159101.SZ) [2] - The Hang Seng Internet ETF (513330.SH) targets major internet companies in Hong Kong such as Alibaba, Baidu, Tencent, and NetEase, while the Hong Kong Stock Connect Technology ETF (159101.SZ) also includes leading innovative pharmaceutical companies [2] - These ETFs are listed on mainland stock exchanges and support T+0 intra-day trading, providing A-share investors with low-threshold access without the need for cross-border accounts or currency exchange [2]

Summary of Key Points from Conference Call Industry Overview - The conference call discusses the global business development (BD) activities in the pharmaceutical sector during the Chinese New Year period from February 13 to February 23, 2026, highlighting a total of 18 BD transactions globally [1] Core Insights and Arguments - **Key Transactions**: - Qinhai Bio licensed its MAT2A inhibitor (GH31), which has received IND approval in China and the US and is currently in Phase I clinical trials, to Gilead. Qinhai will receive an upfront payment of $80 million, $1.45 billion in milestone payments, and a tiered double-digit percentage royalty based on net sales [1] - Other notable transactions include: - Novartis partnered with Unnatural Products to develop macrocyclic peptide drugs, focusing on cardiovascular applications, with Unnatural Products receiving an upfront payment of $100 million and potential milestone payments of $1.7 billion [1] - Eli Lilly acquired global rights for the IL6 monoclonal antibody clazakizumab from CSL for all indications except end-stage renal disease, with CSL receiving an upfront payment of $100 million [1] - Merck collaborated with Mayo Clinic to integrate clinical and genomic data, focusing on early research translation in inflammatory bowel disease, skin diseases, and neurology [1] - **Year-to-Date Transactions**: - From January 1 to February 23, 2026, there have been 36 BD transactions involving Chinese companies, with 13 of these transactions involving multinational corporations (MNCs) [1] Additional Important Insights - **Comparison with Previous Year**: - In comparison, there were 26 BD transactions during the same period in 2025, with only 3 involving MNCs [2] - **Future Outlook**: - The analysis indicates that MNCs have increased their focus on Chinese BD teams and asset searches since the second half of 2025, suggesting a positive outlook for more BD transactions involving Chinese assets and MNCs in 2026 [2]

Core Viewpoint - BeiGene's subcutaneous formulation of Tislelizumab has received implied approval from the National Medical Products Administration for clinical trial supplementation, aimed at treating malignant tumors, marking a significant advancement in drug formulation that is expected to enhance patient compliance and market potential [1] Stock Performance - As of February 13, 2026, BeiGene's A-shares (688235) were priced at 279.62 CNY, with a 5-day cumulative increase of 2.61%; Hong Kong shares (06160) were at 208.60 HKD, up 1.66% over the same period; while U.S. shares (ONC.OQ) were at 346.07 USD, down 2.22% [2] - On February 13, 2026, A-share net outflow of main funds was 8.49 million CNY, with a trading volume of 316 million CNY, indicating short-term profit-taking pressure influenced by market sentiment and company events [2] Financial Report Analysis - BeiGene plans to release its financial results for Q4 and the full year of 2025 on February 26, 2026; preliminary data shows a revenue of 27.595 billion CNY for the first nine months of 2025, a year-on-year increase of 44.21%, and a net profit attributable to shareholders of 1.139 billion CNY, up 130.88% year-on-year [3] - The high growth in performance is primarily driven by the sales expansion of core products like Tislelizumab, with investors advised to focus on annual profitability and globalization progress [3] Institutional Perspectives - In the past 90 days, 9 institutions have rated BeiGene, with 8 giving a buy rating and 1 an outperform rating, setting a target average price of 320.0 CNY [4] - Analysts indicate that the company's fundamentals are robust, with strong globalization progress and profitability, although financial risks and market competition should be monitored [4]

Core Insights - The company has achieved significant global growth over the past year, marking a critical turning point towards profitability with its core self-developed BTK inhibitor, Baiyueze, establishing a leading position globally [1] - The company has launched its second self-developed product in the hematology field, the BCL2 inhibitor Baiyueda (Sotuximab), which is now commercially available [1] - The company has expanded its global footprint, with products available in over 75 markets and more than 2 million patients receiving treatment worldwide [1] Global Expansion and Market Impact - In Thailand, the approval process for Baizean took only 7 months, significantly reducing the time for patients to access innovative treatments [2] - In India, two self-developed products have benefited over 1,500 patients with positive clinical feedback [2] - The company is supporting the first immunotherapy clinical trial in sub-Saharan Africa through the provision of PD-1 inhibitors [2] - The Guangzhou production base not only serves domestic patients but also extends to markets in Indonesia, India, and South Korea, continuously expanding the company's global reach [2] Commitment to Innovation and Accessibility - The company aims to enhance drug accessibility in more countries and regions while continuing to expand its pipeline with a focus on scientific innovation [3] - The commitment to making innovative treatments available to more patients globally is seen as a long-term investment and a driving force for the company [3] Milestone Year - The year 2025 is highlighted as a milestone for the company, marking its 15th anniversary and a clearer, more determined new starting point in its globalization journey [4] Collaboration and Knowledge Sharing - The company emphasizes the importance of collaboration with various industry stakeholders to gather diverse experiences and insights, aiming to illuminate hope for more patients through scientific exploration [5]

Core Insights - Recent developments for BeiGene include the approval of a supplemental application for the subcutaneous formulation of Tislelizumab for malignant tumor treatment, which is expected to enhance patient compliance and market potential [1] - The company plans to release its financial results for Q4 and the full year of 2025 on February 26, 2026, which will be followed by a board meeting and a conference call for investors [1] Stock Performance - BeiGene's stock has shown volatility recently, with A-shares closing at 279.62 CNY, down 1.09% on February 13, 2026, but up 2.61% over the past five days; Hong Kong shares closed at 208.60 HKD, down 0.48%, with a 1.66% increase over five days; and US shares at 350.12 USD, up 1.07% on the same day but down 1.07% over five days [2] - On February 12, 2026, A-share main funds experienced a net outflow of 18.68 million CNY, with a trading volume of 311 million CNY, indicating some profit-taking pressure amid market sentiment [2] Financial Analysis - Preliminary data shows that for the first nine months of 2025, BeiGene reported revenue of 27.595 billion CNY, a year-on-year increase of 44.21%, and a net profit attributable to shareholders of 1.139 billion CNY, up 130.88% [3] - The significant growth in performance is primarily driven by the sales expansion of core products like Tislelizumab, and investors should pay attention to the company's profitability and globalization progress in the upcoming financial report [3]

Group 1 - The year 2025 marks a milestone for the company, celebrating its 15th anniversary and entering a clearer phase in its globalization process [2] - The company achieved significant global growth in the past year, reaching a critical profitability turning point, with its core self-developed BTK inhibitor, Baiyueze, establishing a leading position globally [2] - The company launched its second self-developed product in the hematology field, the BCL2 inhibitor Baiyueda (Sotukral), which is now commercially available [2] Group 2 - In Thailand, the approval process for Baizean took only 7 months, significantly reducing the time for patients to access innovative treatments [3] - In India, the company's two self-developed products have benefited over 1,500 patients, receiving positive clinical feedback [3] - The company is expanding its global footprint by supporting local commercialization efforts in Indonesia and providing PD-1 inhibitors for clinical trials in sub-Saharan Africa [3] Group 3 - The company's goals for 2026 remain clear: to continue pipeline expansion centered on science and to enhance drug accessibility for patients in more countries [4] - The commitment to making innovations accessible to more patients is seen as a long-term investment and a driving force for the company [4] - The company emphasizes the importance of collaboration with industry partners to gather diverse experiences and wisdom from different regions to improve patient outcomes globally [4]

Group 1 - The core viewpoint of the article highlights the performance of the CSI 500 Growth ETF managed by Huaxia Fund Management, which has seen a return of 29.67% since its inception on July 19, 2022, and a return of 0.82% over the past month [1][1][1] - As of the midday close on February 13, the CSI 500 Growth ETF (159620) fell by 0.77%, trading at 1.289 yuan with a transaction volume of 893,900 yuan [1][1][1] - The top holdings of the CSI 500 Growth ETF include stocks such as Ruichuang Micro-Nano, which rose by 0.94%, and Changchuan Technology, which increased by 2.50%, while stocks like Hehe Information and Dazhu CNC experienced declines of 1.37% and 0.15%, respectively [1][1][1] Group 2 - The performance benchmark for the CSI 500 Growth ETF is the return rate of the CSI Smart Selection 500 Growth Innovation Strategy Index [1][1][1] - The fund is managed by Huaxia Fund Management Company, with Rong Ying serving as the fund manager [1][1][1]